

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Transmembrane anion transport and cytotoxicity of synthetic tambjamine analogs†

Elsa Hernando,^a Vanessa Soto-Cerrato,^b Susana Cortés-Arroyo,^b Ricardo Pérez-Tomás^b and Roberto Quesada^{*a}

5 Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

Ten synthetic analogs of the marine alkaloids tambjamines, bearing aromatic enamine moieties, have been synthesized. These compounds proved to be highly efficient transmembrane anion transporters in model liposomes. Changes in the electronic nature of the substituents of the aromatic enamine or the
10 alkoxy group of the central pyrrole group did not affect this anionophore activity. The *in vitro* activity of these compounds has also been studied. They triggered apoptosis in several cancer cell lines with IC₅₀ values in the low micromolar range as well as modify the intracellular pH inducing the basification of acidic organelles.

Introduction

15 The development of small molecules capable of facilitating the transmembrane transport of ions is an active field of research.¹ These compounds can mimic the activity of natural ionophores, which are widely used as antibiotics and tools for biomembrane research.² Their potential as future anticancer drugs and
20 chemotherapeutics in conditions related to the dysfunction of natural transport mechanisms is starting to be recognized.³ The majority of these compounds facilitate the transmembrane transport of cations and anion selective ionophores are relatively scarce, the prodiginines being the most representative examples.⁴
25 These compounds display intriguing pharmacological activities, and there is a growing evidence linking the ionophoric activity of these molecules and their cytotoxicity.⁵ These molecules can permeabilize cellular membranes, upsetting the normal ionic balance and modifying the intracellular pH, triggering apoptosis.

30 We decided to study the marine alkaloids tambjamines. These naturally occurring compounds are structurally related to the prodiginines, being characterized by an imine substituted 4-methoxy-1*H*,1'*H*-2,2'-bipyrrole moiety.⁶ Likewise, these compounds have been shown to display antimicrobial and
35 antitumor activities.⁷ The mechanism of action of these compounds is unclear but may involve their ionophoric activity.⁵ We recently reported the anion transport activities of some tambjamine derivatives.⁸ They proved to be very efficient anion exchangers in model liposomes, promoting both chloride and
40 bicarbonate transport. All naturally occurring tambjamines present alkyl substituted imine groups. Nevertheless, during our previous studies, we identified the synthetic tambjamine analog **2**, bearing an aromatic substituent, outperforming the naturally occurring derivatives studied.⁸ Prompted by this result, we
45 decided to explore the anion transport and antiproliferative activities of synthetic tambjamine analogs bearing aromatic

substituents in the enamine moiety as well as the effect of varying the substitution of the alkoxy substituent of the bipyrrole.

Results and discussion

50 Compounds **1-10** were synthesised by acid catalyzed condensation of the 4-alkoxy-2,2'-bipyrrole aldehyde and the corresponding amine (Fig. 1).⁹ The products were obtained in good yields as orange-yellow solids in the form of hydrochloric salts. In their protonated form, these compounds are stable for
55 several weeks in organic solutions. We decided to explore aromatic enamine groups bearing both electron donating and electron withdrawing substituents as well as a heteroaromatic (pyridine) group. We also decided to modify the substitution of the pyrrole ring replacing the methoxy group characteristic of the
60 naturally occurring derivatives by a benzyloxy group. Compounds **1** and **2** were previously reported by us.⁸




Fig. 1 Synthetic tambjamine analogs 1-10.

The ¹H NMR spectra of these compounds provide evidence of

a strong interaction of the chloride anion with the tambjamine derivative through the hydrogen cleft formed by the bypyrrole-enamine moiety. Chloride binding in solution was studied by ^1H NMR titration experiments of perchlorate salts of compounds **1-10** with tetrabutylammonium chloride (TBACl) in DMSO- d_6 /0.5% water. Perchlorate salts of **1-10** were prepared by washing crude reaction mixtures with diluted aqueous perchloric acid. Addition of TBACl resulted in the effective replacement of the perchlorate anion by chloride, as evidenced by the ^1H NMR spectra indistinguishable from that of the corresponding hydrochloric salt. Fitting of the data obtained in the ^1H NMR titration experiments using WinEQNMR2 software provided a quantitative assessment of the chloride binding affinity for **1-10** under these conditions (Table 1).¹⁰ The values of the association constants were found to be similar for all the compounds. Thus the electronic character of the aromatic substituent as well as the nature of the alkoxy substitution of the central pyrrole ring had little influence in the calculated K_a value. Although the electronic nature of the aromatic substituent should influence the binding capability of the molecule, it should be noted that the binding process involved both the dissociation of the perchlorate anion and the coordination of chloride. Thus, since perchlorate is also bound by these compounds this effect was not reflected in the values of the calculated association constants.

Table 1: Association constants (K_a , M^{-1}) of compounds **1-10** with chloride (added as tetrabutylammonium salt) determined from ^1H NMR titration experiments in DMSO- d_6 /0.5 H_2O at 293 K.

Compound	K_a (M^{-1})	Compound	K_a (M^{-1})
1	1592 ± 25	6	1428 ± 30
2	1990 ± 122	7	1498 ± 48
3	1789 ± 222	8	1491 ± 59
4	1681 ± 107	9	1836 ± 114
5	1510 ± 157	10	1960 ± 219

Interestingly, the chemical shift of the NH_1 proton (see ESI for two-dimensional NMR data) remained almost unaltered during the titration experiments with tetrabutylammonium chloride whereas that of the C-H group in the 3' position experienced an important downfield shift (Fig. 2). This result is in agreement with the involvement of the C-H₃' proton in the binding of chloride. Gale and colleagues have described a similar anion binding behaviour for a pyrrole group.¹¹




Fig. 2 Stack plot of partial ^1H NMR of compound **4** in DMSO- d_6 /0.5 H_2O solution with the addition of increasing amounts of tetrabutylammonium chloride.

40 Anion transport assays

The transmembrane anion transport activity of compounds **1-10** was explored in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes. Using a chloride selective electrode, the chloride efflux from chloride loaded vesicles was monitored over time, according to reported methods.¹² The EC_{50} , defined as the concentration of carrier needed to induce a 50% chloride release in the time scale of our experiments (300 seconds), was calculated using hill plot analyses (Table 2). All the compounds proved to be very efficient anion transporters with EC_{50} values in the submicromolar range and down to nanomolar levels for the most efficient derivatives in the chloride/nitrate exchange assay.

Table 2: Transport activities expressed as EC_{50} (nM) of compounds **1-10**


Compound	EC_{50} (nM)		Hill parameter n	
	$\text{NO}_3^-/\text{Cl}^-^a$	$\text{NO}_3^-/\text{Cl}^-$	$\text{HCO}_3^-/\text{Cl}^-^b$	$\text{HCO}_3^-/\text{Cl}^-$
1	40 ± 2	1.17 ± 0.09	460 ± 70	0.89 ± 0.1
2	50 ± 8	1.14 ± 0.3	240 ± 40	1.19 ± 0.2
3	140 ± 6	1.18 ± 0.07	890 ± 80	1.04 ± 0.09
4	70 ± 5	1.39 ± 0.2	460 ± 60	0.90 ± 0.1
5	20 ± 9	0.92 ± 0.3	260 ± 30	1.05 ± 0.08
6	80 ± 10	1.32 ± 0.3	370 ± 50	1.12 ± 0.2
7	60 ± 3	1.20 ± 0.09	880 ± 300	0.67 ± 0.1
8	720 ± 70	1.04 ± 0.09	11920 ± 1000	1.11 ± 0.1
9	70 ± 3	1.45 ± 0.1	430 ± 100	0.99 ± 0.1
10	40 ± 2	1.24 ± 0.1	170 ± 20	1.10 ± 0.1

^avesicles loaded with 488 mM NaCl dispersed in 488 mM NaNO_3 (5 mM phosphate buffer, pH 7.2). ^bvesicles loaded with 451 mM NaCl dispersed in 150 mM Na_2SO_4 (20 mM phosphate buffer, pH 7.2) upon addition of a NaHCO_3 pulse to make the extravascular bicarbonate concentration 40 mM.

The transport activity was found to be dependent of the nature of the extravascular anion. Thus, the EC_{50} values were found to be roughly an order of magnitude lower when nitrate was used as external anion instead of bicarbonate. This result reflected the higher lipophilicity of nitrate compared to bicarbonate. The lack of significant chloride efflux when sulfate was the only extravascular anion further supported anion exchange as the transport mechanism accounting for the activity of these compounds (Fig. 3). A Hill parameter value around 1 was consistent with a non cooperative effect and a carrier mechanism for the transmembrane transport activity of these compounds (Table 2).

Similarly to the results observed in the quantification of the chloride binding affinity, the nature of the aromatic substituent showed little effect in the ionophoric efficiency of these compounds. Compounds bearing both electron withdrawing and electron donor substituents promoted anion transport with excellent activity. The trifluoromethyl substituted compounds **3** and **8** were found to be the less active derivatives, with **8** displaying the highest EC_{50} values. When performing transport experiments using this compound precipitation of the added carrier was evident. It could be possible that the comparatively lower efficiency of **8** was due to the failure to partition into the liposome membranes. Compound **5** was found to be the most efficient chloride/nitrate exchanger with a calculated EC_{50} of 20 nM. This derivative outperforms our previously reported carrier **2** (see fig. S106).

The replacement of the methoxy group of the central pyrrole ring, found in all the naturally occurring derivatives, by a benzyloxy group did not result in an important modification of the transport efficiency of these derivatives. For this set of 5 compounds, comparable results for the parent -OMe and -OBn derivatives were observed. This was an unexpected result. We anticipated that this change would affect to the overall lipophilicity of the molecule, a parameter that has been shown by us and others to profoundly influence the activity of 10 transmembrane anion transporters.¹³ It could be that in this case the lipophilicity range of these molecules is adequate to achieve an important activity as carriers and the modifications introduced in the central pyrrole ring did not result in lipophilicity values outside this adequate range.



15 **Fig. 3** Comparative of chloride efflux induced by compound **4** (0.5 μM , 0.1% mol) from: a) POPC liposomes loaded with NaCl (488 mM NaCl and 5 mM phosphate buffer, pH 7.2) immersed in NaNO_3 (494 mM NaNO_3 and 5 mM phosphate buffer, pH 7.2); b) vesicles containing NaCl (451 mM NaCl and 20 mM phosphate buffer, pH 7.2) immersed in Na_2SO_4 (150 mM, Na_2SO_4 ; 40 mM HCO_3^- and 20 mM phosphate buffer, pH 7.2); c) vesicles loaded with NaCl (451 mM NaCl and 20 mM phosphate buffer, pH 7.2) immersed in Na_2SO_4 (150 mM, Na_2SO_4 ; 20 mM phosphate buffer, pH 7.2); d) control experiment (10 μL DMSO): vesicles 20 loaded with NaCl (451 mM NaCl and 20 mM phosphate buffer, pH 7.2) immersed in Na_2SO_4 (150 mM, Na_2SO_4 ; 20 mM phosphate buffer, pH 7.2). All traces are an average of at least three independent experiments.

Biological studies

We decided to study the *in vitro* antitumor activity of compounds 30 **1-10**. A single point screening (10 μM) on a panel of different cancer cell lines (Human melanoma (A375), human lung carcinoma (A549), human colorectal adenocarcinoma (SW620), human mammary adenocarcinoma (MDA-MB-231)) using the MTT assay revealed the important cytotoxicity of these 35 derivatives (Fig. 4).




Fig. 4 Single point screening of synthetic tambjamine analogs **1-10** (10 μM) on a panel of cancer cell lines (A375, A549, SW620, MDA-MB-231). Cell viability measured using the MTT assay after 48 h treatment.

40 The concentration that causes 50% growth inhibition (IC_{50} values) was determined for **1-10** on melanoma (A375) and mammary adenocarcinoma (MDA-MB-231) human cancer cell lines as well as human mammary epithelial (MCF-10A) cell lines (Table 3). Compounds **2** and **7** were found to be the most 45 cytotoxic compounds in these assays, with IC_{50} values ranging from 1.10 to 2.49 μM . On the other hand compound **5** displayed significantly higher IC_{50} values, around 18 μM . Replacement of the O-Me group by an O-Bn substituent resulted in an enhancement of the cytotoxicity of these compounds with 50 average IC_{50} values of 8.90 μM for the -OMe substituted **1-5** and 4.71 μM for the -OBn substituted **6-10** respectively for the cancer lines examined. This effect was specially marked for the pyridine substituted pair **5** and **10**. Little discrimination between normal and cancerous cell lines was observed and significant 55 toxicity against the non cancerous human mammary epithelial cell line MCF-10A line was detected. Average IC_{50} values on this cell line for compounds **1-5** was 12.70 μM and 10.56 μM for compounds **6-10** respectively.

Table 3: IC_{50} of compounds **1-10** on human melanoma (A375), human 60 mammary adenocarcinoma (MDA-MB-231) and human mammary epithelial (MCF-10A) cell lines.

Compound	IC_{50} (μM)	IC_{50} (μM)	IC_{50} (μM)
	A375	MDA-MB-231	MCF-10A
1	8.19 \pm 2.90	6.58 \pm 1.01	10.90 \pm 4.34
2	1.10 \pm 0.01	2.28 \pm 0.56	2.36 \pm 0.01
3	5.20 \pm 0.08	8.13 \pm 1.56	4.12 \pm 1.13
4	8.30 \pm 2.44	13.67 \pm 4.31	26.27 \pm 8.76
5	17.48 \pm 1.94	18.11 \pm 1.16	19.86 \pm 1.79
6	1.56 \pm 0.69	4.71 \pm 2.87	4.90 \pm 1.53
7	1.18 \pm 0.04	2.49 \pm 0.65	2.80 \pm 0.72
8	1.29 \pm 0.11	3.85 \pm 1.39	3.90 \pm 1.28
9	6.75 \pm 2.85	19.11 \pm 0.67	36.50 \pm 4.72
10	2.74 \pm 0.53	3.43 \pm 1.68	4.70 \pm 1.79

In order to analyze the cell death induced by these compounds we used Hoechst 33342 staining (Fig. 5). This DNA 65 binding dye allows the differentiation of apoptosis from other cell death mechanisms. In contrast to untreated cells (control), cells treated with compounds **1-10** showed stronger blue fluorescence indicating chromatin condensation, fragmentation and apoptotic bodies formation, along with “bean” shaped nuclei. All these 70 features are hallmarks of apoptosis.




Fig. 5 Hoechst 33342 staining on melanoma (A375) human cancer cell line. a) Untreated (control) cells; b)-k) cells treated with compounds **1-10**. Treated cells showed typical features of apoptotic processes.




Fig. 6 Acridine orange staining on melanoma (A375) human cancer cell line. a) Untreated (control) cells; b)-k) cells treated with compounds **1-10**. Treated cells showed significant disappearance of orange fluorescence due to basification of acidic organelles.

5 Finally, vital staining with acridine orange (AO) was used to evaluate the effects of these compounds on the intracellular pH levels. Protonation and accumulation of this dye in acidic compartments such as lysosomes results in a characteristic orange fluorescence emission, whereas it emits green fluorescence at higher pH.¹⁴ Human melanoma (A375) cells were stained with AO and granular orange fluorescence was observed in the cytoplasm, corresponding to acidic organelles (Fig. 6). Treatment of these cells with compounds **1-10** resulted in the disappearance of the orange fluorescence, suggesting the basification of acidic organelles. The observed qualitative results correlate well with the antiproliferative activity of these derivatives. The effect was more evident for the most cytotoxic compounds whereas the action of the less toxic derivatives such as **5** led only to minimal changes and appearance similar to untreated cells.

20

Conclusions

Synthetic analogs of tambjamine alkaloids bearing aromatic enamine substituents represent privileged structures for the development of highly efficient transmembrane anion transporters. These compounds efficiently promoted nitrate and bicarbonate/chloride exchange in model liposomes at very low concentrations. At this stage it is unclear which parameters make these compounds so effective as anionophores and studies aimed to shed light on this matter are currently underway in our laboratories. *In vitro* studies showed that they were able to alter the intracellular pH levels, triggering apoptosis in different cancer cell lines with IC₅₀ values in the low micromolar range. The toxicity of these compounds is an important issue to be addressed in order to continue their development as potential anticancer drugs. The tolerance of this motif regarding changes in both the electronic nature of the aromatic enamine substituent as well as the alkoxy group of central pyrrole ring suggest that it could be possible to introduce modifications aimed to increase the selectivity toward cancer cells without losing their anionophoric properties.

45

Experimental section

General Procedures and Methods

Commercial reagents were used as received without any further purification. NMR spectra were recorded in Varian Mercury-300 MHz and Varian Unity Inova-400 MHz spectrometers. Chemical shifts are reported in ppm with using residual solvent peak as reference, coupling constants are reported in Hz. High resolution mass spectra (HRMS) were recorded on a Micromass Autospec S-2 spectrometer using EI at 70eV. 4-Methoxy-2,2'-bipyrrrole-5-carboxaldehyde and 4-Benzyloxy-2,2'-bipyrrrole-5-carboxaldehyde were prepared as described.¹⁵ ¹H NMR titrations experiments were performed in DMSO-*d*₆/H₂O 99.5:0.5 mixtures at 303 K. Data fitting was carried out using WinEQNMR2 software (see the Supporting Information for details).⁹

Synthesis of tambjamine analogs

Compounds **1-10** were synthesised using modifications of the previously reported method.⁹ To a mixture of the 2,2'-bipyrrrole-5-carboxaldehyde (190 mg, 1 mmol,) and the corresponding amine (1.3-3 mmol, 1.3-3 equivalents) in 10 mL of chloroform, 40 μ L of acetic acid were added. The mixture was stirred at 60 °C until TLC showed disappearance of the starting material. The reaction was then diluted with 40 mL of dichloromethane and washed with HCl 1M (3 x 25 mL). The organic fraction was dried over Na₂SO₄ and the solvent evaporated to yield **1-10** as yellow-orange solids in good to excellent yields.

(Z)-1-(4-methoxy-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-phenylmethanimine (1). Yield 94 %. ¹H NMR (300 MHz, DMSO-*d*₆): δ 13.61 (s, NH, 1H), 11.07 (d, NH, 1H, *J* = 14.3 Hz), 10.63 (s, NH, 1H), 7.61 (d, 1H, *J* = 14.1 Hz), 7.28 (t, 4H, *J* = 5.2 Hz), 7.13 – 7.05 (m, 1H), 7.01 (d, 1H, *J* = 1.1 Hz), 6.76 (s, 1H), 6.21 (m, 1H), 5.95 (s, 1H), 3.86 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 165.47 (C), 144.58 (C), 138.60 (C), 130.02 (CH), 129.96 (CH), 125.88 (CH), 125.34 (CH), 122.65 (C), 117.17 (CH), 115.17 (CH), 113.60 (C), 111.57 (CH), 92.40 (CH), 59.03 (CH₃); HRMS (EI) *m/z* calcd for [C₁₆H₁₅N₃O] 265.1215; found: 265.1208.

(Z)-N-(4-(tert-butyl)phenyl)-1-(4-methoxy-1H,1'H-[2,2'-bipyrrrol]-5-yl)methanimine (2). Yield 95 %. ¹H NMR (300 MHz, CDCl₃): δ = 13.94 (s, NH, 1H), 11.22 (d, NH, *J* = 14.4 Hz, 1H), 10.70 (s, NH, 1H), 7.77 (d, NH, *J* = 14.6 Hz, 1H), 7.40 (d, *J* = 8.6 Hz, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.25 (s, 1H), 7.13 (s, 1H), 6.81 (s, 1H), 6.32 (d, *J* = 1.5 Hz, 1H), 6.00 (s, 1H), 3.98 (s, 3H), 1.31 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ = 165.01 (C), 149.16 (C), 143.95 (C), 135.97 (C), 130.15 (CH), 126.71 (CH), 124.99 (CH), 122.53 (C), 116.88 (CH), 114.67 (CH), 113.17 (C), 111.27 (CH), 92.06 (CH), 58.79 (CH₃), 34.58 (C), 31.31 (CH₃); HRMS (EI) *m/z* calcd for [C₂₀H₂₃N₃O] 321.1841; found: 321.1844.

(Z)-1-(4-methoxy-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-(4-(trifluoromethyl)phenyl)methanimine (3). Yield 80 %. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 13.29 (s, NH, 1H), 12.58 (d, NH, *J* = 13.9 Hz, 1H), 12.13 (s, NH, 1H), 8.31 (d, *J* = 13.7 Hz, 1H), 7.77 (s, 4H), 7.29 (s, 2H), 6.61 (s, 1H), 6.36 (s, 1H), 4.01 (s, 3H). ¹³C NMR (75 MHz, DMSO): δ = 166.37 (C), 145.47 (C), 142.22 (C), 131.32 (CH), 127.00 (c, *J*_{C-F} = 3.7 Hz CH), 126.12 (CH), 124.99 (c, *J*_{C-F} = 32.2 Hz, C), 124.22 (c, *J*_{C-F} = 271.1 Hz, CF₃) 121.95 (C), 117.53 (CH), 114.00 (CH), 113.90 (C), 111.57

(CH), 92.98 (CH), 59.13 (CH₃). HRMS (EI) *m/z* calcd for [C₁₇H₁₄F₃N₃O] 333.1089; found: 333.1088.

(Z)-1-(4-methoxy-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-(4-methoxyphenyl)methanimine (4). Yield 92 %. ¹H NMR (300 MHz, CDCl₃): δ = 13.65 (s, 1H), 11.17 (d, *J* = 13.7 Hz, 1H), 10.58 (s, 1H), 7.64 (d, *J* = 13.8 Hz, 1H), 7.36 – 7.22 (m, 2H), 7.07 (s, 1H), 6.93 – 6.81 (m, 2H), 6.76 (d, *J* = 1.3 Hz, 1H), 6.26 (d, *J* = 1.7 Hz, 1H), 5.94 (s, 1H), 3.91 (s, 3H), 3.77 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ = 164.71 (C), 157.83 (C), 143.42 (C), 131.86 (C), 130.43 (CH), 124.88 (CH), 122.65 (C), 118.59 (CH), 115.05 (CH), 114.35 (CH), 112.89 (C), 111.24 (CH), 91.91 (CH), 58.76 (CH₃), 55.65 (CH₃). HRMS (EI) *m/z* calcd for [C₁₇H₁₇N₃O₂] 295.1321; found: 295.1322.

(Z)-1-(4-methoxy-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-(pyridin-2-yl)methanimine (5). Yield 65 %. ¹H NMR (300 MHz, CDCl₃): δ = 13.85 (s, NH, 1H), 11.41 (d, *J* = 13.1 Hz, NH, 1H), 10.73 (s, NH, 1H), 8.63 (d, *J* = 13.4 Hz, 1H), 8.33 (d, *J* = 4.0 Hz, 1H), 7.69 (s, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.16 (s, 1H), 7.08 (dd, *J* = 7.3, 5.0 Hz, 1H), 6.88 (s, 1H), 6.34 (s, 1H), 6.02 (d, *J* = 1.8 Hz, 1H), 4.00 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ = 166.68 (C), 150.02 (C), 148.49 (CH), 145.97 (C), 138.92 (CH), 128.83 (CH), 126.23 (CH), 122.40 (C), 120.69 (CH), 116.04 (CH), 114.73 (C), 113.85 (CH), 111.79 (CH), 92.47 (CH), 58.98 (CH₃). HRMS (EI) *m/z* calcd for [C₁₅H₁₄N₄O] 266.1168; found: 266.1168.

(Z)-1-(4-(benzyloxy)-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-phenylmethanimine (6). Yield 94 %. ¹H NMR (300 MHz, CDCl₃): δ = 14.03 (s, NH, 1H), 11.28 (d, NH, *J* = 14.5 Hz, 1H), 10.73 (s, NH, 1H), 7.83 (d, *J* = 14.6 Hz, 1H), 7.45 (d, *J* = 1.4 Hz, 4H), 7.41 – 7.38 (m, 3H), 7.26 (dd, *J* = 1.5, 0.6 Hz, 2H), 7.20 (s, 1H), 7.15 (s, 1H), 6.83 (s, 1H), 6.33 (dt, *J* = 3.5, 2.1 Hz, 1H), 6.06 (s, 1H), 5.20 (s, 2H). ¹³C NMR (75 MHz, CDCl₃): δ = 164.17 (C), 144.49 (C), 138.52 (C), 134.79 (C), 130.21 (CH), 129.94 (CH), 129.07 (CH), 128.97 (CH), 128.26 (CH), 125.93 (CH), 125.46 (CH), 122.55 (C), 117.27 (CH), 115.11 (CH), 113.81 (C), 111.45 (CH), 93.13 (CH), 73.88 (CH₂). HRMS (EI) *m/z* calcd for [C₂₂H₁₉N₃O] 341.1528; found: 341.1515.

(Z)-N-(4-(benzyloxy)-1H,1'H-[2,2'-bipyrrrol]-5-yl)methylene-4-(tert-butyl)aniline (7). Yield 92 %. ¹H NMR (300 MHz, CDCl₃): δ = 13.83 (s, NH, 1H), 11.23 (d, NH, *J* = 14.5 Hz, 1H), 10.69 (s, NH, 1H), 7.73 (d, *J* = 14.4 Hz, 1H), 7.61 – 7.13 (m, 9H), 7.05 (s, 1H), 6.78 (s, 1H), 6.27 (s, 1H), 6.07 (s, 1H), 5.18 (s, 2H), 1.29 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ = 163.86 (C), 149.36 (C), 143.97 (C), 136.01 (C), 134.84 (C), 130.53 (CH), 129.03 (CH), 128.95 (CH), 128.22 (CH), 126.79 (CH), 125.22 (CH), 122.59 (C), 117.10 (CH), 114.75 (CH), 113.49 (C), 111.32 (CH), 93.00 (CH), 73.77 (CH₂), 34.66 (C), 31.36 (CH₃). HRMS (EI) *m/z* calcd for [C₂₆H₂₇N₃O] 397.2154; found: 397.2165.

(Z)-1-(4-(benzyloxy)-1H,1'H-[2,2'-bipyrrrol]-5-yl)-N-(4-(trifluoromethyl)phenyl)methanimine (8). Yield 44 %. ¹H NMR (300 MHz, CDCl₃): δ = 14.03 (s, NH, 1H), 11.32 (d, NH, *J* = 13.3 Hz, 1H), 10.73 (s, NH, 1H), 7.78 (d, *J* = 14.1 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 7.17 (s, 1H), 6.88 (s, 1H), 6.35 (s, 1H), 6.07 (s, 1H), 5.20 (s, 2H). ¹³C NMR (75 MHz, CDCl₃): δ = 164.93 (C), 146.14 (C), 141.55 (C), 134.49 (CH), 129.33 (CH), 129.12 (CH), 128.90 (C), 128.35 (CH), 127.38 (c, *J*_{C-F} = 33.68 Hz, C), 127.25 (c, *J*_{C-F} = 3.7 Hz, CH), 126.63 (CH), 123.96 (c, *J*_{C-F} = 271.8 Hz, CF₃), 122.36 (C), 117.04 (CH), 116.41 (CH), 115.05

(C), 111.98 (CH), 93.50 (CH), 74.19 (CH₂). HRMS (EI) *m/z* calcd for [C₂₃H₁₈F₃N₃O] 409.1402; found: 409.1402.

(Z)-1-(4-(benzyloxy)-1H,1'H-[2,2'-bipyrrol]-5-yl)-N-(4-methoxyphenyl)methanimine (9). Yield 97 %. ¹H NMR (300 MHz, DMSO): δ = 13.12 (s, 1H), 12.58 (d, *J* = 14.5 Hz, 1H), 11.96 (s, 1H), 8.23 (d, *J* = 14.4 Hz, 1H), 7.69 – 7.50 (m, 4H), 7.40 (ddd, *J* = 8.5, 7.7, 3.6 Hz, 3H), 7.24 – 7.12 (m, 2H), 7.00 (d, *J* = 9.0 Hz, 2H), 6.61 (d, *J* = 1.9 Hz, 1H), 6.30 (d, *J* = 2.2 Hz, 1H), 5.30 (s, 2H), 3.75 (s, 3H). ¹³C NMR (75 MHz, DMSO): δ = 163.40 (C), 157.45 (C), 142.47 (C), 135.53 (C), 132.88 (CH), 131.85 (C), 128.55 (CH), 128.37 (CH), 127.95 (CH), 124.56 (CH), 122.16 (C), 119.12 (CH), 114.93 (CH), 112.49 (C), 112.24 (CH), 110.89 (CH), 93.25 (CH), 72.82 (CH₂), 55.47 (CH₃). HRMS (EI) *m/z* calcd for [C₂₃H₂₁N₃O₂] 371.1634; found: 371.1635.

(Z)-1-(4-(benzyloxy)-1H,1'H-[2,2'-bipyrrol]-5-yl)-N-(pyridin-2-yl)methanimine (10). Yield 46 %. ¹H NMR (300 MHz, DMSO): δ = 13.21 (s, 1H), 12.82 (s, 1H), 12.20 (s, 1H), 8.50 (s, 1H), 8.38 (dd, *J* = 4.9, 1.5 Hz, 1H), 7.87 (td, *J* = 7.7, 1.6 Hz, 1H), 7.55 (dd, *J* = 7.9, 1.6 Hz, 2H), 7.43 (dd, *J* = 11.1, 3.8 Hz, 3H), 7.34 – 7.15 (m, 4H), 6.70 (s, 1H), 6.37 (s, 1H), 5.32 (s, 2H). ¹³C NMR (75 MHz, DMSO): δ = 165.39 (C), 149.82 (C), 148.80 (CH), 145.75 (C), 139.48 (CH), 135.13 (C), 128.71 (CH), 128.49 (CH), 127.75 (CH), 126.28 (CH), 121.86 (C), 120.98 (CH), 114.11 (CH), 113.98 (C), 112.92 (CH), 111.64 (CH), 93.89 (CH), 73.38 (CH₂). HRMS (EI) *m/z* calcd for [C₂₁H₁₈N₄O] 342.1481; found: 342.1490.

Preparation of Phospholipid Vesicles

A chloroform solution of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC) (20 mg/mL) (Sigma-Aldrich) was evaporated *in vacuo* using a rotary evaporator and the lipid film obtained was dried under high vacuum for at least 2 hours. The lipid film was rehydrated by addition of a sodium chloride solution (488 mM NaCl and 5 mM phosphate buffer, pH 7.2 or 451 mM NaCl and 20 mM phosphate buffer, pH 7.2) and followed by careful vortexing. The lipid suspension was then subjected to nine freeze-thaw cycles and twenty-nine extrusions through a 200 nm polycarbonate Nucleopore membrane using a LiposoFast Basic extruder (Avestin, Inc.). The resulting unilamellar vesicles were dialyzed against NaNO₃ solution (488 mM NaNO₃ and 5 mM phosphate buffer, pH 7.2) or a Na₂SO₄ solution (150 mM Na₂SO₄ and 20 mM phosphate buffer, pH 7.2) to remove unencapsulated chloride.

ISE Transport Assays

Unilamellar vesicles (200 nm mean diameter) composed of POPC containing an encapsulated solution of 488 mM NaCl and 5 mM phosphate buffer, pH 7.2 or 451 mM NaCl and 20 mM phosphate buffer, pH 7.2, were suspended in a solution 494 mM NaNO₃ and 5 mM phosphate buffer, pH 7.2 or 150 mM Na₂SO₄ and 20 mM phosphate buffer, pH 7.2 respectively, for a final lipid concentration of 0.5 mM and a total volume of 5 mL. A DMSO solution of the carrier molecule, typically 5 μL to avoid influence of the solvent molecules in the assay, was added and the chloride release from vesicles was monitored using a symphony combination chloride electrode. At the end of the experiment the vesicles were lysed with detergent (triton-X 10% dispersion in water, 20 μL) to release all chloride ions; the resulting value was

considered to represent 100% release and used as such. For the bicarbonate anion exchange assays to the vesicles suspended in a Na₂SO₄ solution of NaHCO₃ (150 mM in Na₂SO₄ buffered to pH 7.2 with 20 mM sodium phosphate salts) was added for a final concentration of 40 mM and the chloride efflux was monitored for another 5 minutes before they were lysed with detergent to release all chloride ions; the resulting value was considered to represent 100% release and used as such. For the experiments using NaNO₃ as external solution vesicles containing an encapsulated solution of 488 mM NaCl and 5 mM phosphate buffer, were suspended in a 494 mM NaNO₃ and 5 mM phosphate buffer, pH 7.2 solution.

Cell lines and Culture Conditions

Human melanoma (A375), human lung carcinoma (A549), human colorectal adenocarcinoma (SW620), human mammary adenocarcinoma (MDA-MB-231) and human mammary epithelial (MCF-10A) cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in DMEM medium (Biological Industries) supplemented with 10% heat-inactivated foetal bovine serum (FBS; Life Technologies, Carlsbad, CA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L- glutamine, all from Biological Industries. MDA-MB-231 cell line was cultured in DMEM:F12 media (1:1, Biological Industries) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L- glutamine. MCF10A cell line was cultured in DMEM:F12 media (1:1) supplemented with 5% horse serum (Life Technologies), 20 ng/ml EGF, 0.5 μg/ml Hydrocortisone, 100 ng/ml Cholera toxin, 10 μg/ml insulin all from Sigma-Aldrich Chemical Co. (St. Louis, MO) and 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L- glutamine. Cells were grown at 37°C in a 5% CO₂ atmosphere.

Cell Viability Assay

Cells (1 x 10⁵ cells/ ml) were seeded in 96-well plates and allowed to grow for 24 h. Afterwards, they were treated with 10 μM of each compound for single point experiments and dose response curves were performed ranging from 0.39 to 50 μM for 48 h to calculate the inhibitory concentration of 50% of cell population (IC₅₀) values of the most potent compounds. Cell viability was determined by MTT assay. After treatment, 10 μM of 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich) was added to each well for an additional 4 h. DMSO was added in control cells. Media was aspirated and the blue MTT formazan precipitate was dissolved in 100 μl of DMSO. The absorbance at 570 nm was measured on a multiwell plate reader. Cell viability was expressed as a percentage of control cells, and data are shown as the mean value ± S.D. of three independent experiments performed in triplicate for single point evaluation or in duplicate for dose-response curves. IC₅₀ values were calculated with GraphPad Prism 5 software.

Acridine Orange Staining

A375 cells (10⁵ cells/ ml) were seeded on glass slices and 48 h later they were treated with IC₅₀ value during 1:30 h. DMSO was added in control cells. Afterwards, cells were washed twice with PBS and incubated in 5 μg/ml acridine orange solution during 30 min at room temperature. Finally, they were washed with PBS-

10% FBS three times and examined by fluorescence in a NIKON eclipse E800 microscope (SCT filter 330/380nm).

Hoechst Staining

A375 cells (10^5 cells/ml) were seeded in 12-well plates, allowed to grow for 24 h and then treated with 10 μ M of each compound for 48 h. DMSO was added in control cells. They were washed in PBS, resuspended in 2 μ g/ml Hoechst 33342 (Sigma-Aldrich Chemical Co.) and incubated for 30 min at 37°C in the dark. Finally, cells were washed in PBS and examined by fluorescence in a NIKON eclipse E800 microscope (SCT filter 330/380nm).

Acknowledgements

The authors gratefully acknowledge Andrea Sancho for contributions to the synthesis. This research was supported by Consejería de Educación de la Junta de Castilla y León (Project BU340U13) and Fundació la Marató de TV3.

Notes and references

- (a) N. Busschaert and P. A. Gale, *Angew. Chem. Int. Ed.*, 2013, **52**, 1374–1382; (b) N. Sakai and S. Matile, *Langmuir*, 2013, **29**, 9031–9040; (c) S. Matile, A. Vargas Jentzsch, J. Montenegro and A. Fin, *Chem. Soc. Rev.*, 2011, **40**, 2453–2474; (d) J. T. Davis, O. Okunola and R. Quesada, *Chem. Soc. Rev.*, 2010, **39**, 3843–3862; (e) C. J. E. Haynes and P. A. Gale, *Chem. Commun.*, 2011, **47**, 8203–8209; (f) T. M. Fyles, *Chem. Soc. Rev.*, 2007, **36**, 335–347; (g) A. P. Davis, D. N. Sheppard and B. D. Smith, *Chem. Soc. Rev.*, 2007, **36**, 348–357; (h) S. Hussain, P. R. Brotherhood, L. W. Judd and A. P. Davis, *J. Am. Chem. Soc.*, 2011, **133**, 1614–1617; (i) S. Bahmanjah, N. Zhang and J. T. Davis, *Chem. Commun.*, 2012, **48**, 4432–4434; (j) W. A. Harrell, Jr., M. L. Bergmeyer, P. Y. Zavaliy and J. T. Davis, *Chem. Commun.*, 2010, **46**, 3950–3952.
- (a) M. M. Faul and B. E. Huff, *Chem. Rev.*, 2000, **100**, 2407–2473; (b) I. Alfonso and R. Quesada, *Chem. Sci.*, 2013, **4**, 3009–3019.
- (a) X. Li, B. Shen, X.-Q. Yao and D. Yang, *J. Am. Chem. Soc.*, 2009, **131**, 13676–13680; (b) B. Shen, X. Li, X. Yao, D. Yang, *PLoS ONE*, 2012, **7**, e34694; (c) C.-R. Elie, M. Charbonneau and A. R. Schmitzer, *MedChemComm.*, 2012, **3**, 1231–1234; (d) S. Rastogi, E. Marchal, I. Uddin, B. Groves, J. Colpitts, S.A. McFarland, J. T. Davis and A. Thompson, *Org. Biomol. Chem.*, 2013, **11**, 3834–3845; (e) S. J. Moore, M. Wenzel, M. E. Light, R. Morley, S. J. Bradberry, P. Gomez-Iglesias, V. Soto-Cerrato, R. Perez-Tomas and P. A. Gale, *Chem. Sci.*, 2012, **3**, 2501–2508.
- (a) A. Fürstner, *Angew. Chem. Int. Ed.*, 2003, **42**, 3582–3603; (b) N. R. Williamson, P. C. Fineran, F. J. Leeper and G. P. C. Salmond, *Nature Rev. Microbiol.*, 2006, **4**, 887–899; (c) N. R. Williamson, P. C. Fineran, T. Gristwood, S. R. Chawrai, F. J. Leeper and G. P. C. Salmond, *Future Microbiol.*, 2007, **2**, 605–618; (d) M. S. Melvin, M. W. Calcutt, R. E. Nofle and R. A. Mandeville, *Chem. Res. Toxicol.*, 2002, **15**, 742–748; (e) R. Pérez-Tomás, B. Montaner, E. Llagostera and V. Soto-Cerrato, *Biochem. Pharmacol.*, 2003, **66**, 1447–1452.
- (a) P. A. Gale, R. Pérez-Tomás and R. Quesada, *Acc. Chem. Res.*, 2013, **46**, 2801–2813; (b) B. Díaz de Greñu, P. Iglesias Hernández, M. Espona, D. Quiñero, M. E. Light, T. Torroba, R. Pérez Tomás, and R. Quesada, *Chem. Eur. J.*, 2011, **17**, 14074–14083.
- (a) B. Carté and D.J. Faulkner, *J. Org. Chem.*, 1983, **48**, 2314–2318; (b) A. J. Blackman and C. P. Li, *Aust. J. Chem.*, 1994, **47**, 1625–1629; (c) R. A. Davis, A. R. Carroll and R. J. Quinn, *Aust. J. Chem.*, 2001, **54**, 355–359.
- (a) M. Carbone, C. Irace, F. Costagliola, F. Castelluccio, G. Villani, G. Calado, V. Padula, G. Cimino, J. L. Cervera, R. Santamaria and M. Gavagnin, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 2668–2670; (b) L. N. Aldrich, S. L. Stoops, B. C. Crews, L. J. Marnett and C. W. Lindsley, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 5207–5211; (c) D. M. Pinkerton, M. G. Banwell, M. J. Garson, N. Kumar, M. O. de

- Moraes, B. C. Cavalcanti, F. W. A. Barros and C. Pessoa, *Chemistry & Biodiversity*, 2010, **7**, 1311–1324; (d) F. Ballestrero, T. Thomas, C. Burke, S. Egan and S. Kjelleberg, *Appl. Environ. Microbiol.*, 2010, **76**, 5710–5717.
- P. Iglesias Hernández, D. Moreno, A. Araujo Javier, T. Torroba, R. Pérez-Tomás and R. Quesada, *Chem. Commun.*, 2012, **48**, 1556–1558.
- D. M. Pinkerton, M. G. Banwell and A. C. Willis, *Org. Lett.*, 2007, **9**, 5127–5130.
- M. J. Hynes, *J. Chem. Soc. Dalton Trans.*, 1993, 311–312.
- I. E. D. Vega, P. A. Gale, M. E. Light and S. J. Loeb, *Chem. Commun.*, 2005, 4913–4915.
- A. V. Koulov, T. N. Lambert, R. Shukla, M. Jain, J. M. Boon, B. D. Smith, H. Li, D. N. Sheppard, J.-B. Joos, J. P. Clare and A. P. Davis, *Angew. Chem.*, 2003, **115**, 5081–5083; *Angew. Chem. Int. Ed.*, 2003, **42**, 4931–4933.
- (a) V. Saggiomo, S. Otto, I. Marques, V. Félix, T. Torroba and R. Quesada, *Chem. Commun.*, 2012, **48**, 5274–5276; (b) N. Busschaert, S. J. Bradberry, M. Wenzel, C. J. E. Haynes, J. R. Hiscock, I. L. Kirby, L. E. Karagiannidis, S. J. Moore, N. J. Wells, J. Herniman, G. J. Langley, P. N. Horton, M. E. Light, I. Marques, P. J. Costa, V. Félix, J. G. Frey and P. A. Gale, *Chem. Sci.*, 2013, **4**, 3036–3045.
- A. C. Allison and M. R. Young, *Lysosomes in Biology and Pathology*, Vol. 2., 1969, North-Holland Publishing Co., Amsterdam.
- K. Dairi, S. Tripathy, G. Attardo and J.-F. Lavalée, *Tetrahedron Lett.* 2006, **47**, 2605–2606.

⁹⁰ *a* Departamento de Química, Facultad de Ciencias, Universidad de Burgos, 09001 Burgos, Spain. E-mail: rquesada@ubu.es

b Department of Pathology and Experimental Therapeutics, Cancer Cell Biology Research Group, Universidad de Barcelona, Barcelona, Spain. E-mail: rperez@ub.edu

⁹⁵ † Electronic supplementary information (ESI) available: spectral characterization data, details of anion binding and anion transport experiments. See DOI: 10.1039/b000000x/